Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naive Subjects Infected With Genotype 1 Chronic Hepatitis C

Next Previous
Search
Trial Profile

A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naive Subjects Infected With Genotype 1 Chronic Hepatitis C

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDX 184 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme

    • Most Recent Events

    • 15 Oct 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 13 Nov 2009 Planned end date changed from 1 May 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 02 Nov 2009 Results have been presented at AASLD 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top